Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer and other tumor types, has announced its participation in two major investor conferences.

The company will participate in:

• The TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside discussion scheduled for March 3, 2025, at 11:50 a.m. ET
• The Leerink Global Healthcare Conference in Miami, FL, with a fireside discussion scheduled for March 10, 2025, at 9:20 a.m. ET

Live webcasts and archived recordings of both events will be accessible through the 'Events & Presentations' tab on the Investors & Media section of Zentalis' website.

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET.
• Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET.

Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.

About Zentalis Pharmaceuticals
Zentalis^® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Contact:

Haibo Wang - Chief Business Officer
Ron Moldaver - Investor Relations
ir@zentalis.com

FAQ

When is Zentalis (ZNTL) presenting at the TD Cowen Healthcare Conference in 2025?

Zentalis will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 11:50 a.m. ET in Boston, MA.

What time is ZNTL's presentation at the Leerink Global Healthcare Conference 2025?

Zentalis will present at the Leerink Global Healthcare Conference on March 10, 2025, at 9:20 a.m. ET in Miami, FL.

How can investors access Zentalis (ZNTL) conference presentations in March 2025?

Investors can access live webcasts and archived recordings of both presentations through the 'Events & Presentations' tab on the Investors & Media section of Zentalis' website.

What type of cancer treatment is Zentalis (ZNTL) developing?

Zentalis is developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types.